新斯的明对老年非心脏手术患者早期术后认知功能障碍的影响:双盲安慰剂对照随机对照试验
本研究为双盲安慰剂对照随机对照试验,纳入118例≥65岁非心脏手术老年患者,术后分别接受新斯的明0.04 mg/kg或生理盐水。新斯的明组术后第1天POCD发生率显著降低(-22%,95%CI -37至-7),但第3天和第7天无显著差异;
要点
- 新斯的明0.04 mg/kg可降低老年非心脏手术患者术后第1天POCD发生率。
- 新斯的明对术后第3天和第7天POCD无显著影响。
- 新斯的明可能通过抑制氧化应激和升高BDNF发挥早期认知保护作用。
核心结论
- 新斯的明降低了老年非心脏手术患者术后第1天的POCD发生率。
- 新斯的明抑制氧化应激并升高血清BDNF水平。
- 新斯的明对术后第3天和第7天POCD无显著影响。
研究设计与样本
- 双盲、安慰剂对照、随机对照试验,纳入118例≥65岁接受非心脏手术的老年患者。
- 术后分配至新斯的明组(0.04 mg/kg)或安慰剂对照组(生理盐水)。
主要发现
- 新斯的明组术后第1天POCD发生率较安慰剂组降低22%(95%CI -37至-7)。
- 术后第3天POCD发生率差异为8%(95%CI -4至20),第7天为3%(95%CI -7至13)。
关键数值与推荐
- POCD诊断标准为简易智力状态检查(MMSE)和蒙特利尔认知评估(MoCA)的Z评分均≤-1.96。
- 新斯的明剂量为0.04 mg/kg,术后给药。
- 采用多变量回归分析并调整阿托品剂量以评估新斯的明对POCD发生率的影响。
临床怎么用
- 对于≥65岁非心脏手术患者,术后使用新斯的明0.04 mg/kg可能降低术后第1天POCD发生率。
- 新斯的明的认知保护作用主要体现在术后早期,对第3天和第7天无显著影响。
- 临床决策需结合患者个体情况,新斯的明对POCD的临床影响有待进一步研究。
局限性
- 研究仅纳入118例患者,样本量有限。
- 新斯的明对POCD的临床影响需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of this study was to investigate the efficacy of neostigmine on postoperative cognitive dysfunction (POCD) and determine its effect on systematic markers of oxidative stress in older patients. METHODS: This double-blind placebo-controlled trial enrolled 118 elderly patients (≥65 years) undergoing noncardiac surgeries who were allocated to a neostigmine treatment group (0.04 mg/kg) or a placebo control group (normal saline) postoperatively. POCD was diagnosed if the Z -scores for the mini-mental state examination and the Montreal Cognitive Assessment were both ≤-1.96. Postoperative serum levels of malondialdehyde (MDA), superoxide dismutase (SOD), and brain-derived neurotrophic factor (BDNF) were also compared. Multivariable regression analysis with dose adjustment of atropine was used to demonstrate the influence of neostigmine on the incidence of POCD. RESULTS: Patients receiving neostigmine had a significantly reduced incidence of POCD compared to patients who were treated with placebo on the first day after surgery (-22%, 95% confidence interval [CI], -37 to -7), but not on the third (8%, 95% CI, -4 to 20) or seventh day after surgery (3%, 95% CI, -7 to 13). Postoperative plasma MDA levels were significantly lower ( P = .016), but SOD and BDNF levels were increased ( P = .036 and .013, respectively) in the neostigmine group compared to the control group on the first day after surgery. CONCLUSIONS: Neostigmine reduced POCD on the first day after noncardiac surgery in older patients. Neostigmine treatment inhibited oxidative stress and increased serum BDNF levels. There was no significant influence of neostigmine on POCD on the third or seventh day after surgery. The clinical influence of neostigmine on POCD should be further investigated.
引用
- Deng C, Yang L, Sun D, et al. Influence of Neostigmine on Early Postoperative Cognitive Dysfunction in Older Adult Patients Undergoing Noncardiac Surgery: A Double-Blind, Placebo-Controlled, Randomized Controlled Trial. Anesth Analg. 2024. PMID: 38100389. doi:10.1213/ANE.0000000000006687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。